Please provide your email address to receive an email when new articles are posted on . Chart review yielded 38 persons with MS and cancer treated with immune checkpoint inhibitors. Thirteen patients ...

Disability progression independent of relapse activity (PIRA) -- sometimes referred to as silent progression -- is a key integrating concept in the contemporary view of multiple sclerosis (MS). "The ...

Autologous hematopoietic cell transplantation, compared with CAR-T cell therapy, resulted in lower rates of relapse and improved progression-free survival in patients with relapsed large B-cell ...

Please provide your email address to receive an email when new articles are posted on . Data were analyzed from 709 participants given ozanimod or interferon in two different trials trials. At 6 ...

“Our data add and expand previous observations on silent progression in MS and are consistent with the view of the disease as a single continuum, in which RAW [relapse-associated worsening] and PIRA ...

Clinical outcomes from routine practice confirm ocrelizumab effectiveness in relapsing MS, with low rates of disability worsening over 4 years.

Increases in sGFAP during BCDT are linked to disability progression in MS, independent of relapse activity. sGFAP is a stronger predictor of disease progression than sNfL, reflecting different ...